The Drugs Controller General of India (DCGI) has recommended an Emergency Use Authorization (EUA) for Bharat Biotech’s Covaxin for children between 6 and 12 years old. The DCGI also recommended EUA for Corbevax for children ages 5 to 12 and ZyCoV-D for Zydus Cadila for those over 12, sources told CNBC-TV18.
The Subject Matter Expert Committee (SEC) had suggested modifications to the protocols for Covaxin.
Covaxin, one of the major vaccines given to adults in India, is currently given to children aged 15-18 and all adults. The vaccine is given in two doses, with an interval of 28 days between the first and the second dose.
Covaxin got emergency use list from World Health Organization on November 3, 2021. This vaccine is an inactivated whole virion vaccine against COVID-19, developed in partnership with Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
In January this year, DCGI gave permission to Bharat Biotech for COVID BBV154 intranasal booster dose trials.
First post: STI